Enter assignee name

EPO Patents = 1

Trademarks = 3

Forward Citations = 13

Loading Chart...

7 inventors (with patents filed for the assignee):

Arban Domi (11 out of 12 patents)

Farshad Guirakhoo (8 out of 9 patents)

Harriet L Robinson (8 out of 19 patents)

4. Nathanael Paul McCurley (8 out of 9 patents)

5. Michael Salant Hellerstein (6 out of 6 patents)

6. Rahul Basu (1 out of 2 patents)

7. Ming Luo (1 out of 4 patents)

13 patents: Sort by Forward Citations

1. 12370249 - Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus glycoprotein (GP) and matrix protein (VP40) (2025-07-29),

2. 12329808 - Compositions and methods for generating an immune response to treat or prevent malaria (2025-06-17),

3. 12247214 - Vaccinia viral vectors encoding chimeric virus like particles (2025-03-11),

4. 11897919 - Multivalent HIV vaccine boost compositions and methods of use (2024-02-13),

5. 11896657 - Replication-deficient modified vaccinia Ankara (MVA) expressingglycoprotein (GP) and matrix protein (VP40) (2024-02-13),

6. 11857611 - Compositions and methods for generating an immune response to treat or prevent malaria (2024-01-02),

7. 11701418 - Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) (2023-07-18),

8. 11638750 - Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein (2023-05-02),

9. 11413341 - Vaccinia viral vectors encoding chimeric virus like particles (2022-08-16),

10. 11311612 - Compositions and methods for generating an immune response to treat or prevent malaria (2022-04-26),

11. 11278607 - Compositions and methods for generating an immune response to a tumor associated antigen (2022-03-22),

12. 11098086 - Multivalent HIV vaccine boost compositions and methods of use (2021-08-24),

13. 11052148 - Compositions and methods for generating an immune response to hepatitis B virus (2021-07-06),

GeoVax, Inc. is a clinical-stage biotechnology company developing innovative human vaccines for infectious diseases through its novel Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) platform technology. The company's primary focus is on developing vaccines for HIV, Zika virus, and hemorrhagic fever viruses. GeoVax's vaccines are designed to elicit immune responses that provide protection against a wide range of disease-causing pathogens. With a strong pipeline of vaccine candidates and a commitment to improving global health, GeoVax is leading the way in vaccine development and disease prevention.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

13 Patents

#4 in Smyrna, GA

#473 in Georgia

#23,099 in US

#43,615 in the World

Smyrna, GA, United States of America

Geovax, Inc.